Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Symbiter Forte
- Development stage
- Unknown
- Lead developer
- O.D. Prolisok
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Symbiter Forte is a concentrated multicomponent probiotic (live biotherapeutic product) developed by the Ukrainian company O.D. Prolisok. It consists of a symbiotic consortium of 14 to 24 strains of live beneficial bacteria, including various species of *Lactobacillus*, *Bifidobacterium*, *Propionibacterium*, and *Acetobacter*. Unlike many commercial probiotics that use lyophilized (freeze-dried) bacteria, Symbiter Forte is provided as a liquid concentrate, which maintains the microorganisms in an active physiological state, allowing for immediate colonization and metabolic activity upon ingestion. The product is primarily indicated for the restoration of gut microbiota in patients with severe dysbiosis, gastrointestinal infections, and those recovering from intensive antibiotic or radiation therapy. Its mechanism of action involves the competitive exclusion of pathogens, the production of organic acids, vitamins, and bacteriocins, and the modulation of the host's mucosal immune system.
- Brand names
- Symbiter ForteСимбитер ФортеSymbiter Forte M
- Other names
- SymbiterСимбитер
Beyond the preview
Go deeper on Symbiter Forte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Symbiter Forte.